|PhaseRx Inc -- USA Stock|| |
USD 0.28 0.0194 6.47%
Dr. Oliver W. Press, Ph.D., M.D., is CoFounder of PhaseRx, Inc. He is also a Member of the Fred Hutchinson Cancer Research Center and a Professor of Medicine at the University of Washington . Dr. Press received both his Doctor of Medicine and PhD from the University of Washington after completing his undergraduate studies at Stanford University. He performed an internship and residency at Massachusetts General Hospital and served as a clinical fellow at Harvard Medical School. He is currently the recipient of the Dr. Penny E. Petersen Memorial Chair for Lymphoma Research at FHCRC and served as Associate Director of the University of Washington Medical Scientist Training Program for over 15 years. He was also the Director of Clinical Research for Hematology and Hematologic Malignancies for the UWFHCRC Cancer Center Consortium from 2006 to 2008. He is currently the CoDirector of the UW Center for Intracellular Delivery of Biologics. Dr. Press has recently been chosen by his peers to be the CoChair of Lymphoma Steering Committee of the National Cancer Institute and has served as the Chair of the Scientific Advisory Board of the Lymphoma Research Foundation and of the Follicular Lymphoma Consortium .
The company has return on total asset (ROA)
of (64.2) %
which means that it has lost $64.2 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (228.17) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 5.44 M in liabilities with Debt to Equity (D/E) ratio of 264.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PhaseRx Inc has Current Ratio of 2.1 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy. On December 11, 2017, PhaseRx, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. PhaseRx operates under Biotechnology classification in USA and traded on BATS Exchange exchange. It employs 10 people.PhaseRx Inc (PZRX) is traded on BATS Exchange in USA. It is located in WASHINGTON, U.S.A and employs 10 people. PhaseRx is listed under Pharmaceutical Products category by Fama And French industry classification.